Anshul Vagrecha

Dr. Anshul Vagrecha

Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SBSakshi Bami
Sakshi Bami
AVAnshul Vagrecha
Anshul Vagrecha
DSDanielle Soberman
Danielle Soberman
MBMohamad Badawi
Mohamad Badawi
DCDaniel Cannone
Daniel Cannone
CLCarolyn Fein Levy
Carolyn Fein Levy

9 March 2022 in Biology
Verified
Journal Article
Open access
PDF file
AVAnshul Vagrecha
Anshul Vagrecha
MZMingce Zhang
Mingce Zhang
SASuchitra Acharya
Suchitra Acharya
SLShannon Lozinsky
Shannon Lozinsky
ASAaron Singer
Aaron Singer
RCRandy Q. Cron
Randy Q. Cron
Multisystem inflammatory syndrome in children (MIS-C) affects few children previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In 2020, 45 children admitted to our hospital for MIS-C underwent genetic screening with a commercial 109-immune-gene panel. Thirty-nine children were diagnosed with MIS-C, and 25.4% of the 39 MIS-C patients harbored rare heterozygous missense mutations either in primary hemophagocytic lymphohistiocytosis (pHLH) genes (LYST, STXBP2, PRF1, UNC13D, AP3B1) or the HLH-associated gene DOCK8 (four variants). We demonstrate that foamy virus introduction of cDNA for the four DOCK8 variants into human NK-92 natural killer (NK) cells led to decreased CD107a expression (degranulation) and decreased NK cell lytic function in vitro for each variant. Heterozygous carriers of missense mutations in pHLH genes and DOCK8 may serve as risk factors for development of MIS-C among children previously infected with SARS-CoV-2.

15 June 2023 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
AVAnshul Vagrecha
Anshul Vagrecha
VTVincent Tao
Vincent Tao
RCRosemarie Corless
Rosemarie Corless
CCCassandra Colon
Cassandra Colon
ARArlene Redner
Arlene Redner
MAMark Atlas
Mark Atlas
BackgroundPegylated form of E. coli derived asparaginase (PEG) is a crucial component of pediatric ALL therapy. Patients who develop a hypersensitivity (HSR) reaction with PEG receive an alternative form - Erwinia asparaginase (EA). However, an international shortage in 2017 had made it challenging to treat these patients. We have developed a comprehensive strategy to address this need.Patients and methodsThis is a single center, retrospective analysis. All patients receiving PEG were premedicated to reduce infusion reactions. Patients who developed HSR underwent PEG desensitization. Patients were compared to historic controls.ResultsFifty-six patients were treated within the study period. There was no difference in the frequency of reactions before and after the adoption of universal premedication (p = 0.78). Eight patients (14.2%) developed either >= Grade 2 HSR or silent inactivation and 5 patients (62.5%) successfully underwent desensitization. The remaining three patients received EA asparaginase. This intervention led to a decrease in PEG substitution, with 3 patients (5.3%) requiring EA compared to 8 patients (15.09%) in the pre-intervention period. (p = 0.11) PEG desensitization was more cost effective than EA administration.ConclusionPEG desensitization is a safe, cost effective, and practical alternative in children with ALL and a Grade 2 or higher HSR.

26 December 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
ATAdit L. Tal
Adit L. Tal
KBKayleen A. Bailey
Kayleen A. Bailey
ACAlexander Chou
Alexander Chou
KOKatharine Offer
Katharine Offer
JRJeremy Rosenblum
Jeremy Rosenblum
JLJennifer Levine
Jennifer Levine

11 January 2021 in Haemophilia
Verified
Journal Article
Open access
PDF file
AVAnshul Vagrecha
Anshul Vagrecha
JSJoseph Stanco
Joseph Stanco
SMSumreen Majeed
Sumreen Majeed
PKPeter Kouides
Peter Kouides
SASuchitra S. Acharya
Suchitra S. Acharya
Click on the article title to read more.

1 June 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
RCRandy Q. Cron
Randy Q. Cron
MZM. Zhang
M. Zhang
DADevin Absher
Devin Absher
JBJ. Bridges
J. Bridges
ASA. Schnell
A. Schnell
WCW. Chatham
W. Chatham
Background: We recently identified DOCK8 as a novel gene associated with cytokine storm syndrome (CSS)1. Heterozygous missense mutations in DOCK8 diminish NK cell lytic function and contribute to increased pro-inflammatory cytokine production (CSS). CSS is a potential complication of COVID-19 with severe consequences2. Children are at risk of a SARS-CoV-2 post-infectious CSS, multisystem inflammatory syndrome in children (MIS-C)3. Host genetic factors associated with COVID-19 CSS and MIS-C CSS are unknown. Objectives: The goals are to identify and functionally study rare mutations in DOCK8 in patients with SARS-CoV-2 COVID-19 and MIS-C. Methods: To date, 16 adult patients enrolled in a COVID-19 CSS clinical trial at UAB had whole genome sequencing. Four (25%) had rare heterozygous DOCK8 mutations (3 missense, 1 intronic). A COVID-19 CSS adult patient in Seattle also had a DOCK8 missense mutation. In addition, DOCK8 missense mutations were identified in five children (UAB & Northwell) hospitalized with MIS-C. DOCK8 mutations, or wild-type (WT) sequence controls, were introduced into human NK-92 cells by FOAMY virus transduction. WT and mutant DOCK8-expressing NK-92 cells were incubated with K562 target cells and compared for cytolysis and degranulation (CD107a). Results: One COVID-19 patient DOCK8 mutation (Gly523Arg) reduced NK cell degranulation by 30% and cytolysis by 23% (n=3) (Figure 1). Similar studies of 3 MIS-C patients with DOCK8 missense mutations (Arg899Trp, Ala2Thr, Pro687Leu) revealed up to 31% reduced NK cell degranulation and 48% reduction in cytolysis by 3 distinct mutations (n=3). Two-way ANOVA analysis revealed statistically significant (p<0.05) differences in NK cell degranulation and lysis for four unique DOCK8 mutations. Conclusion: Heterozygous DOCK8 missense mutations may contribute to severe COVID-19 and MIS-C CSS by partial dominant-negative effects yielding decreased NK cell cytolysis. References: [1]Schulert GS, Cron RQ. The genetics of macrophage activation syndrome. Genes Immun 2020:21:169-181. [2] Cron RQ, Chatham WW. The rheumatologist’s role in COVID-19. J Rheumatol 2020:47:639-642. [3]Reiff D, Mannion ML, Samuy N, Scalici P, Cron RQ. Distinguishing active pediatric COVID-19 from MIS-C. Pediatr Rheumatol Online J, in press. Disclosure of Interests: Randy Cron Consultant of: SOBI, Novartis, Pfizer, Sironax, Grant/research support from: SOBI, Mingce Zhang: None declared, Remy Cron: None declared, Devin Absher: None declared, John Bridges: None declared, Amanda Schnell: None declared, Pavan Bhatraju: None declared, Anshul Vagrecha: None declared, Shannon Lozinsky: None declared, Suchitra Acharya: None declared, Carolyn Levy: None declared, Winn Chatham Grant/research support from: SOBI.